Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Recombinant HPV 6/11 Bivalent Vaccine in Healthy Volunteers
NCT02405520Phase 1Completed
- Start
- Mar 2015
- Primary completion
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of recombinant human papillomavirus type 6/11 bivalent vaccine in condylomata acuminata (4 arms). Primary endpoint: Adverse reactions/events at 10 months. Started Mar 2015; status: completed.
02
Drugs
recombinant human papillomavirus type 6/11 bivalent vaccine
03
Conditions
condylomata acuminata
Beyond the preview
Go deeper on NCT02405520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405520.